Scared to Go Through Opiate Withdrawl Again

Sci Pract Perspect. 2002 Jul; 1(1): xiii–20.

The Neurobiology of Opioid Dependence: Implications for Treatment

Thomas R. Kosten

¹ Yale Academy School of Medicine New Haven, Connecticut

² VA Connecticut Healthcare Arrangement West Oasis, Connecticut

Tony P. George

¹ Yale University School of Medicine New Haven, Connecticut

³ Connecticut Mental Wellness Center New Oasis, Connecticut

Abstract

Opioid tolerance, dependence, and addiction are all manifestations of encephalon changes resulting from chronic opioid abuse. The opioid abuser's struggle for recovery is in not bad part a struggle to overcome the effects of these changes. Medications such as methadone, LAAM, buprenorphine, and naltrexone act on the same brain structures and processes equally addictive opioids, simply with protective or normalizing effects. Despite the effectiveness of medications, they must be used in conjunction with appropriate psychosocial treatments.

While the individual patient, rather than his or her disease, is the advisable focus of treatment for opioid corruption, an understanding of the neurobiology of dependence and addiction can exist invaluable to the clinician. It can provide insight well-nigh patient behaviors and problems, aid define realistic expectations, and analyze the rationales for treatment methods and goals. As well, patients who are informed near the brain origins of habit can benefit from understanding that their disease has a biological basis and does not hateful they are "bad" people.

Brain abnormalities resulting from chronic use of heroin, oxycodone, and other morphine-derived drugs are underlying causes of opioid dependence (the need to continue taking drugs to avoid a withdrawal syndrome) and habit (intense drug craving and compulsive apply). The abnormalities that produce dependence, well understood by science, appear to resolve after detoxification, within days or weeks after opioid utilise stops. The abnormalities that produce addiction, withal, are more than wide-ranging, complex, and long-lasting. They may involve an interaction of environmental effects—for instance, stress, the social context of initial opiate use, and psychological conditioning—and a genetic predisposition in the class of encephalon pathways that were abnormal even before the get-go dose of opioid was taken. Such abnormalities can produce craving that leads to relapse months or years after the individual is no longer opioid dependent.

In this commodity we describe how opioids affect brain processes to produce drug liking, tolerance, dependence, and addiction. While these processes, like everything else that happens in the brain, are highly complex, nosotros try to explain them in terms that can exist easily understood and explained to patients. Nosotros besides talk over the handling implications of these concepts. Pharmacological therapy with methadone, LAAM (levoalpha-acetylmethadol), naltrexone, or other medications directly offsets or reverses some of the brain changes associated with habit, greatly enhancing the effectiveness of behavioral therapies. Although researchers do not all the same know everything most how these medications work, it is articulate that they are all truly active treatments, rather than simply substitutes for the addictive opioids.

ORIGINS OF DRUG LIKING

Many factors, both individual and environmental, influence whether a particular person who experiments with opioid drugs volition continue taking them long enough to become dependent or fond. For individuals who do continue, the opioids' ability to provide intense feelings of pleasure is a critical reason.

When heroin, oxycodone, or any other opiate travels through the bloodstream to the brain, the chemicals attach to specialized proteins, called mu opioid receptors, on the surfaces of opiate-sensitive neurons (encephalon cells). The linkage of these chemicals with the receptors triggers the aforementioned biochemical brain processes that advantage people with feelings of pleasure when they engage in activities that promote basic life functions, such as eating and sex. Opioids are prescribed therapeutically to relieve pain, but when opioids activate these reward processes in the absenteeism of significant pain, they can motivate repeated use of the drug but for pleasure.

One of the brain circuits that is activated by opioids is the mesolimbic (midbrain) reward system. This organisation generates signals in a office of the brain called the ventral tegmental area (VTA) that upshot in the release of the chemic dopamine (DA) in another part of the encephalon, the nucleus accumbens (NAc) (Figure 1). This release of DA into the NAc causes feelings of pleasure. Other areas of the encephalon create a lasting record or retentivity that assembly these proficient feelings with the circumstances and environment in which they occur. These memories, chosen conditioned associations, often lead to the craving for drugs when the abuser reen-counters those persons, places, or things, and they drive abusers to seek out more drugs in spite of many obstacles.

The Mesolimbic Reward System

When drugs stimulate mu opioid receptors in the brain, cells in the ventral tegmental area (VTA) produce dopamine and release information technology into the nucleus accumbens (NAc), giving rise to feelings of pleasure. Feedback from the prefrontal cortex (PFC) to the VTA helps the states overcome drives to obtain pleasance through actions that may be dangerous or unwise, simply this feedback appears to be compromised in individuals who become addicted to drugs. The locus ceruleus (LC) is an area of the brain that plays an important role in drug dependence.

Particularly in the early stages of abuse, the opioid'south stimulation of the brain's advantage organization is a chief reason that some people take drugs repeatedly. However, the compulsion to utilize opioids builds over time to extend across a simple bulldoze for pleasure. This increased coercion is related to tolerance and dependence.

OPIOID TOLERANCE, DEPENDENCE, AND WITHDRAWAL

From a clinical standpoint, opioid withdrawal is one of the about powerful factors driving opioid dependence and addictive behaviors. Treatment of the patient's withdrawal symptoms is based on understanding how withdrawal is related to the brain'due south aligning to opioids.

Repeated exposure to escalating dosages of opioids alters the brain so that information technology functions more than or less commonly when the drugs are present and abnormally when they are non. Two clinically important results of this alteration are opioid tolerance (the need to take higher and college dosages of drugs to reach the same opioid consequence) and drug dependence (susceptibility to withdrawal symptoms). Withdrawal symptoms occur only in patients who have developed tolerance.

Opioid tolerance occurs because the brain cells that have opioid receptors on them gradually become less responsive to the opioid stimulation. For example, more opioid is needed to stimulate the VTA brain cells of the mesolimbic reward system to release the same amount of DA in the NAc. Therefore, more opioid is needed to produce pleasure comparable to that provided in previous drug-taking episodes.

Opioid dependence and some of the most sad opioid withdrawal symptoms stalk from changes in another important encephalon organisation, involving an area at the base of operations of the encephalon—the locus ceruleus (LC) (Figure ii). Neurons in the LC produce a chemical, noradrenaline (NA), and distribute it to other parts of the brain where it stimulates wakefulness, animate, blood pressure, and full general alertness, among other functions. When opioid molecules link to mu receptors on brain cells in the LC, they suppress the neurons' release of NA, resulting in drowsiness, slowed respiration, low blood force per unit area—familiar effects of opioid intoxication. With repeated exposure to opioids, nevertheless, the LC neurons adjust by increasing their level of activeness. Now, when opioids are nowadays, their suppressive bear upon is offset past this heightened action, with the event that roughly normal amounts of NA are released and the patient feels more than or less normal. When opioids are not present to suppress the LC brain cells' enhanced activity, however, the neurons release excessive amounts of NA, triggering jitters, anxiety, muscle cramps, and diarrhea.

The Neurobiological Basis of Dependence and Withdrawal

The locus ceruleus (LC) is an area of the encephalon that is critically involved in the production of opioid dependence and withdrawal. The diagrams show how opioid drugs bear upon processes in the LC that control the release of noradrenaline (NA), a brain chemic that stimulates wakefulness, muscle tone, and respiration, among other functions.

A. Usually, natural opiatelike chemicals produced by the body link to mu opioid receptors on the surface of neurons. This linkage activates an enzyme that converts a chemical called adenosine triphosphate (ATP) into another chemical, called cyclic adenosine monophosphate (cAMP), which in turn triggers the release of NA. Prior to initiation of opioid drug abuse, the neuron produces enough NA to maintain normal levels of alertness, muscle tone, respiration, etc.

B. When heroin or another opioid drug links to the mu opioid receptors, it inhibits the enzyme that converts ATP to cAMP. Equally a consequence, less campsite is produced, less NA is released. Alacrity, muscle tone, and respiration drop, and the acute opioid effects of sedation, shallow breathing, etc., announced.

C. With repeated heroin exposure, the neuron increases its supply of enzyme and ATP molecules. Using these extra raw materials, the neuron can produce enough cAMP to offset the inhibitory effect of the drug and release roughly normal amounts of NA despite the presence of the drug. At this phase, the private no longer experiences the same intensity of acute opioid furnishings as in earlier stages of corruption.

D. When heroin is discontinued after chronic abuse, the drug's inhibitory bear upon is lost. Operating at normal efficiency but with enhanced supplies of converting enzyme and ATP, the neuron produces abnormally high levels of cAMP, leading to excessive release of NA. The patient experiences the clinical symptoms of withdrawal—jitters, anxiety, musculus cramps, etc. If no further drugs are taken, the neuron will largely revert to its predrug condition (panel A) within days or weeks.

Other brain areas in addition to the LC likewise contribute to the production of withdrawal symptoms, including the mesolimbic reward system. For instance, opioid tolerance that reduces the VTA's release of DA into the NAc may prevent the patient from obtaining pleasure from normally rewarding activities such as eating. These changes in the VTA and the DA reward systems, though not fully understood, form an important brain system underlying craving and compulsive drug use.

TRANSITION TO Addiction

Every bit nosotros have seen, the pleasure derived from opioids' activation of the brain'due south natural advantage organization promotes continued drug utilize during the initial stages of opioid habit. Subsequently, repeated exposure to opioid drugs induces the brain mechanisms of dependence, which leads to daily drug utilize to avert the unpleasant symptoms of drug withdrawal. Further prolonged apply produces more long-lasting changes in the brain that may underlie the compulsive drug-seeking behavior and related adverse consequences that are the hallmarks of addiction. Recent scientific research has generated several models to explain how habitual drug apply produces changes in the brain that may lead to drug addiction. In reality, the procedure of addiction probably involves components from each of these models, as well as other features.

Definitions of Key Terms

dopamine (DA): A neurotransmitter present in brain regions that regulate movement, emotion, motivation, and the feeling of pleasance.

GABA (gamma-amino butyric acid): A neurotransmitter in the brain whose chief part is to inhibit the firing of neurons.

locus ceruleus (LC): A region of the brain that receives and processes sensory signals from all areas of the torso; involved in arousal and vigilance.

noradrenaline (NA): A neurotransmitter produced in the brain and peripheral nervous system; involved in arousal and regulation of blood force per unit area, slumber, and mood; too called norepinephrine.

nucleus accumbens (NAc): A structure in the forebrain that plays an important part in dopamine release and stimulant activity; one of the brain'due south key pleasance centers.

prefrontal cortex (PFC): The frontmost part of the encephalon; involved in higher cognitive functions, including foresight and planning.

ventral tegmental area (VTA): The group of dopamine-containing neurons that brand upwards a central part of the encephalon reward system; key targets of these neurons include the nucleus accumbens and the prefrontal cortex

The "Changed Set Indicate" Model

The "changed prepare point" model of drug addiction has several variants based on the altered neurobiology of the DA neurons in the VTA and of the NA neurons of the LC during the early phases of withdrawal and abstinence. The basic idea is that drug abuse alters a biological or physiological setting or baseline. One variant, by Koob and LeMoal (2001), is based on the thought that neurons of the mesolimbic advantage pathways are naturally "set up" to release enough DA in the NAc to produce a normal level of pleasure. Koob and LeMoal suggest that opioids crusade habit by initiating a brutal cycle of changing this set up signal such that the release of DA is reduced when normally pleasurable activities occur and opioids are not nowadays. Similarly, a change in set point occurs in the LC, only in the opposite direction, such that NA release is increased during withdrawal, every bit described in a higher place. Under this model, both the positive (drug liking) and negative (drug withdrawal) aspects of drug addiction are accounted for.

A specific style that the DA neurons can go dysfunctional relates to an alteration in their baseline ("resting") levels of electrical activeness and DA release (Grace, 2000). In this second variant of the changed set up signal model, this resting level is the consequence of two factors that influence the amount of resting DA release in the NAc: cortical excitatory (glutamate) neurons that drive the VTA DA neurons to release DA, and autoreceptors ("brakes") that shut down further release when DA concentrations become excessive. Activation of opioid receptors by heroin and heroin-like drugs initially bypasses these brakes and leads to a large release of DA in the NAc. Withal, with repeated heroin use, the brain responds to these successive large DA releases by increasing the number and force of the brakes on the VTA DA neurons. Eventually, these enhanced "braking" autoreceptors inhibit the neurons' resting DA release. When this happens, the dependent addict will accept fifty-fifty more heroin to offset the reduction of normal resting DA release. When he or she stops the heroin use, a state of DA impecuniousness will consequence, manifesting in dysphoria (pain, agitation, malaise) and other withdrawal symptoms, which tin lead to a cycle of relapse to drug utilise.

A third variation on the set-point modify emphasizes the sensitivity to ecology cues that leads to drug wanting or peckish rather than but reinforcement and withdrawal (Breiter et al., 1997; Robinson and Berridge, 2000). During periods when the drug is not available to addicts, their brains tin remember the drug, and desire or craving for the drug can exist a major factor leading to drug use relapse. This craving may represent increased activeness of the cortical excitatory (glutamate) neurotransmitters, which drive the resting activity of the DA-containing VTA neurons, as mentioned, and also drive the LC NA neurons. Every bit the glutamate activity increases, DA will exist released from the VTA, leading to drug wanting or craving, and NA volition be released from the LC, leading to increased opioid withdrawal symptoms. This theory suggests that these cortical excitatory brain pathways are overactive in heroin addiction and that reducing their activeness would be therapeutic. Scientists are currently researching a medication chosen lamotrigene and related compounds chosen excitatory amino acid antagonists to run across whether this potential handling strategy really can work.

Thus, several mechanisms in the LC and VTA-NAc brain pathways may be operating during addiction and relapse. The excitatory cortical pathways may produce petty response in the VTA during the resting state, leading to reductions in DA. However, when the fond individual is exposed to cues that produce craving, the glutamate pathways may go sufficiently active to raise DA and stimulate want for a greater loftier. This same increase in glutamate activity will raise NA release from the LC to produce a dysphoric state predisposing to relapse and continued addiction.

Cognitive Deficits Model

The cognitive deficits model of drug addiction proposes that individuals who develop addictive disorders have abnormalities in an area of the brain called the prefrontal cortex (PFC). The PFC is important for regulation of judgment, planning, and other executive functions. To help u.s.a. overcome some of our impulses for immediate gratification in favor of more of import or ultimately more rewarding long-term goals, the PFC sends inhibitory signals to the VTA DA neurons of the mesolimbic advantage system.

The cognitive deficits model proposes that PFC signaling to the mesolimbic reward organization is compromised in individuals with addictive disorders, and as a outcome they have reduced ability to use judgment to restrain their impulses and are predisposed to compulsive drug-taking behaviors. Consequent with this model, stimulant drugs such as methamphetamine appear to damage the specific brain circuit—the frontostriatal loop—that carries inhibitory signals from the PFC to the mesolimbic reward system. In addition, a recent study using magnetic resonance spectroscopy showed that chronic alcohol abusers have abnormally low levels of gamma-amino butyric acrid (GABA), the neurochemical that the PFC uses to betoken the reward system to release less DA (Behar et al., 1999). Besides, the cognitive deficits model of drug addiction could explain the clinical observation that heroin addiction is more severe in individuals with hating personality disorder—a condition that is independently associated with PFC deficits (Raine et al., 2000).

In contrast to stimulants, heroin apparently dam-ages the PFC but not the frontostriatal loop. Therefore, individuals who go heroin addicts may accept some PFC damage that is independent of their opioid corruption, either inherited genetically or caused by some other factor or event in their lives. This preexisting PFC harm predisposes these individuals to impulsivity and lack of command, and the boosted PFC damage from chronic repeated heroin abuse increases the severity of these problems (Kosten, 1998).

STRESS AND DRUG CRAVING

That drug abuse patients are more vulnerable to stress than the general population is a clinical truism. In the research loonshit, numerous studies have documented that physical stressors (such every bit footshock or restraint stress) and psychological stressors tin can cause animals to reinstate drug employ and that stressors tin trigger drug craving in addicted humans (e.chiliad., Shaham et al., 2000). The likely explanation for these observations is that opioids raise levels of cortisol, a hormone that plays a principal role in stress responses; and cortisol, in turn, raises the level of activity in the mesolimbic reward organisation (Kreek and Koob, 1998). By these mechanisms, stress may contribute to the abuser's want to take drugs in the kickoff place and to his or her subsequent compulsion to go along taking them.

PHARMACOLOGICAL INTERVENTIONS AND TREATMENT IMPLICATIONS

In summary, the various biological models of drug addiction are complementary and broadly applicable to chemical addictions. Long-term pharmacotherapies for opioid dependence and habit annul or contrary the abnormalities underlying those conditions, thereby enhancing programs of psychological rehabilitation. Short-term treatments for relieving withdrawal symptoms and increasing abstinence are beyond the scope of this article; instead, we refer readers elsewhere for detailed neurobiological explanations of the various nonopioid-based abstinence initiation approaches such as clonidine and clonidine-naltrex-i for rapid detoxification (meet O'Connor and Kosten, 1998, and O'Connor et al., 1997).

The medications most commonly used to treat opioid abuse attach to the brain cells' mu opioid receptors, similar the addictive opioids themselves. Methadone and LAAM stimulate the cells much as the illicit opioids do, but they have different effects considering of their dissimilar durations of action. Naltrexone and buprenorphine stimulate the cells in ways quite distinct from the addictive opioids. Each medication can play a role in comprehensive handling for opioid habit.

Methadone

Methadone is a long-acting opioid medication. Unlike morphine, heroin, oxycodone, and other addictive opioids that remain in the encephalon and body for only a short time, methadone has furnishings that last for days. Methadone causes dependence, but—considering of its steadier influence on the mu opioid receptors—it produces minimal tolerance and alleviates craving and compulsive drug use. In improver, methadone therapy tends to normalize many aspects of the hormonal disruptions found in addicted individuals (Kling et al., 2000; Kreek, 2000; Schluger et al., 2001). For example, it moderates the exaggerated cortisol stress response (discussed above) that increases the danger of relapse in stressful situations.

Methadone handling reduces relapse rates, facilitates behavioral therapy, and enables patients to concentrate on life tasks such as maintaining relationships and holding jobs. Pioneering studies by Dole, Nyswander, and Kreek in 1964 to 1966 established methadone'south efficacy (Dole et al., 1966). As a Drug Enforcement Administration schedule II controlled substance, the medication is administered primarily in federally regulated methadone programs, where careful monitoring of patients' urine and regular drug counseling are critical components of rehabilitation. Patients are more often than not started on a daily dose of xx mg to 30 mg, with increases of five mg to 10 mg until a dose of 60 mg to 100 mg per twenty-four hours is achieved. The higher doses produce full suppression of opioid peckish and, consequently, opioid-free urine tests (Judd et al., 1998). Patients more often than not stay on methadone for 6 months to 3 years, some much longer. Relapse is common amid patients who discontinue methadone after only ii years or less, and many patients have benefited from lifelong methadone maintenance.

LAAM

A longer acting derivative of methadone, LAAM can be given three times per calendar week. Contempo concerns about heart rhythm bug (specifically, prolonged QT interval) have limited LAAM's use (U.S. Food and Drug Assistants, 2001). Nevertheless, long-term maintenance on moderate to high doses of LAAM tin can, like methadone maintenance, normalize physiological functions such as the cortisol stress response (Kling et al., 2000; Kreek, 1992, 2000; Schluger et al., 2001). Dosing with LAAM is highly individualized, and 3-times-weekly doses range from 40 mg to 140 mg.

Naltrexone

Naltrexone is used to help patients avoid relapse after they have been detoxified from opioid dependence. Its master therapeutic action is to monopolize mu opioid receptors in the encephalon then that addictive opioids cannot link up with them and stimulate the encephalon's reward arrangement. Naltrexone clings to the mu opioid receptors 100 times more strongly than opioids practise, but it does non promote the brain processes that produce feelings of pleasure (Kosten and Kleber, 1984). An individual who is adequately dosed with naltrex-one does not obtain any pleasance from addictive opioids and is less motivated to utilise them.

Before naltrexone treatment is started, patients must be fully detoxified from all opioids, including methadone and other handling medications; otherwise, they will exist at risk for severe withdrawal. Naltrexone is given at fifty mg per twenty-four hour period or up to 200 mg twice weekly. Patients' liver office should exist tested before treatment starts, as heroin abusers may have experienced top of sure liver enzymes (transaminases) caused past infectious complications of intravenous drug utilize, such every bit hepatitis (Verebey and Mule, 1986).

Unfortunately, medication compliance is a disquisitional trouble with naltrexone, because unlike methadone or LAAM, naltrexone does not itself produce pleasurable feelings. Poor compliance limits naltrexone's utility to only about 15 percent of heroin addicts (Kosten and Kleber, 1984).

Naltrexone is also sometimes used to rapidly detoxify patients from opioid dependence. In this situation, while naltrexone keeps the addictive opioid molecules away from the mu opioid receptors, clonidine may help to suppress the excessive NA output that is a primary crusade of withdrawal (Kosten, 1990).

Buprenorphine

Buprenorphine's action on the mu opioid receptors elicits 2 unlike therapeutic responses within the brain cells, depending on the dose. At depression doses buprenorphine has effects similar methadone, but at high doses it behaves like naltrexone, blocking the receptors and so strongly that it tin can precipitate withdrawal in highly dependent patients (that is, those maintained on more than 40 mg methadone daily).

Buprenorphine is expected to be approved past the Food and Drug Administration for the treatment of opioid dependence in 2002. Several clinical trials accept shown that when used in a comprehensive treatment program with psychotherapy, buprenorphine is as effective equally methadone, except for patients with heroin addiction and so severe they would crave a dose of more than 100 mg daily (Kosten et al., 1993; Oliveto et al., 1999; Schottenfeld et al., 1997). Buprenorphine offers a safety reward over methadone and LAAM, since high doses precipitate withdrawal rather than the suppression of consciousness and respiration seen in overdoses of methadone, LAAM, and the addictive opioids. Buprenorphine can exist given three times per week. Because of its rubber and user-friendly dosing, it may be useful for treating opioid habit in primary intendance settings, which is particularly helpful since most opioid addicts have significant medical problems (for example, hepatitis B or C and HIV infection). Buprenorphine will be available in four mg and 8 mg tablets. A combination tablet with naloxone (Suboxone) has been developed to negate the reward a user would experience if he or she were to illegally divert and inject the medication. The maintenance dose of the combination tablet can exist up to 24 mg and used for every-other-day dosing.

As office-based handling of heroin habit becomes available, the highest possible condom level (that is, minimal side effects) should be balanced with handling effectiveness. The patient taking methadone must either visit the medical office daily (not viable in about cases) or be responsible for taking daily doses at dwelling, as scheduled. Accordingly, for an opioid-dependent patient who cannot be relied upon to accept the medication as instructed and thus might overdose, buprenorphine in three doses weekly would be a safer pick than methadone. The patient'southward part visits could be limited to once or twice per week, with remaining buprenorphine doses taken at habitation. Too, buprenorphine has less overdose potential than methadone, since it blocks other opioids and even itself equally the dosage increases.

SUMMARY

Opioid dependence and addiction are nearly accordingly understood as chronic medical disorders, like hypertension, schizophrenia, and diabetes. As with those other diseases, a cure for drug addiction is unlikely, and frequent recurrences tin can be expected; merely long-term handling can limit the disease'southward adverse effects and improve the patient'southward solar day-to-day functioning.

The mesolimbic reward system appears to exist cardinal to the development of the straight clinical consequences of chronic opioid abuse, including tolerance, dependence, and addiction. Other brain areas and neurochemicals, including cortisol, as well are relevant to dependence and relapse. Pharmacological interventions for opioid habit are highly effective; all the same, given the complex biological, psychological, and social aspects of the illness, they must be accompanied by appropriate psychosocial treatments. Clinician awareness of the neurobiological basis of opioid dependence, and information-sharing with patients, can provide insight into patient behaviors and problems and clarify the rationale for handling methods and goals.

Acquittance

This piece of work was supported by NIDA grants number P50-DA-1-2762, K05-DA-0-0454, K12-DA-0-0167, R01-DA-1-3672, and R01-DA-1-4039.

REFERENCES

• Behar KL, et al. Preliminary testify of low cortical GABA levels in localized 1H-MR spectra of booze-dependent and hepatic encephalopathy patients. American Journal of Psychiatry. 1999;156(6):952–954. [PubMed] [Google Scholar]
• Breiter HC, et al. Acute effects of cocaine on human brain activity and emotion. Neuron. 1997;nineteen(3):591–611. [PubMed] [Google Scholar]
• Dole VP, Nyswander ME, Kreek MJ. Narcotic occludent. Athenaeum of Internal Medicine. 1966;118(four):304–309. [PubMed] [Google Scholar]
• Grace AA. The tonic/phasic model of dopamine system regulation and its implications for understanding alcohol and stimulant peckish. Addiction. 2000;95(Suppl two):S119–S128. [PubMed] [Google Scholar]
• Judd LL, et al. Effective medical treatment of opiate addiction. Journal of the American Medical Association. 1998;280(22):1936–1943. [PubMed] [Google Scholar]
• Kling MA, et al. Opioid receptor imaging with PET and [18F] cyclofoxy in long-term, methadone-treated old heroin addicts. Journal of Pharmacological and Experimental Therapeutics. 2000;295(3):1070–1076. [PubMed] [Google Scholar]
• Koob GF, LeMoal M. Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology. 2001;24(two):97–129. [PubMed] [Google Scholar]
• Kosten TR. Neurobiology of abused drugs: Opioids and stimulants. Periodical of Nervous and Mental Affliction. 1990;178(4):217–227. [PubMed] [Google Scholar]
• Kosten TR. Pharmacotherapy of cerebral ischemia in cocaine dependence. Drug and Booze Dependence. 1998;49(2):133–144. [PubMed] [Google Scholar]
• Kosten TR, Kleber Hard disk drive. Strategies to improve compliance with narcotic antagonists. American Journal of Drug and Alcohol Abuse. 1984;x(2):249–266. [PubMed] [Google Scholar]
• Kosten TR, Schottenfeld RS, Ziedonis D, Falcioni J. Buprenorphine versus methadone maintenance for opioid dependence. Journal of Nervous and Mental Affliction. 1993;181(six):358–364. [PubMed] [Google Scholar]
• Kreek MJ. Rationale for maintenance pharmacotherapy of opiate dependence. In: O'Brien CP, Jaffe JH, editors. Addictive States. New York: Raven Printing; 1992. pp. 205–230. [Google Scholar]
• Kreek MJ. Methadone-related opioid agonist pharmacotherapy for heroin habit: History, recent molecular and neurochemical research and the hereafter in mainstream medicine. Annals of the NY University of Sciences. 2000;909:186–216. [PubMed] [Google Scholar]
• Kreek MJ, Koob GF. Drug dependence: Stress and dysregulation of brain reward pathways. Drug and Booze Dependence. 1998;51(ane–2):23–47. [PubMed] [Google Scholar]
• O'Connor PG, Kosten TR. Rapid and ultrarapid opioid detoxification techniques. Journal of the American Medical Association. 1998;279(3):229–234. [PubMed] [Google Scholar]
• O'Connor PG, et al. Iii methods of opioid detoxification in a master intendance setting: A randomized trial. Annals of Internal Medicine. 1997;127(7):526–530. [PubMed] [Google Scholar]
• Oliveto AH, et al. Desipramine in opioid-dependent cocaine abusers maintained on buprenorphine versus methadone. Archives of General Psychiatry. 1999;56(ix):812–820. [PubMed] [Google Scholar]
• Raine A, et al. Reduced prefrontal gray matter book and reduced autonomic activity in antisocial personality disorder. Athenaeum of General Psychiatry. 2000;57(two):119–127. [PubMed] [Google Scholar]
• Robinson TE, Berridge KC. The psychology and neurobiology of addiction: An incentive-sensitization view. Addiction. 2000;95(Suppl 2):S91–S117. [PubMed] [Google Scholar]
• Schluger JH, Borg Fifty, Ho A, Kreek MJ. Altered HPA axis responsivity to metyrapone testing in methadone maintained former heroin addicts with ongoing cocaine addiction. Neuropsychopharmacology. 2001;24(5):568–575. [PubMed] [Google Scholar]
• Schottenfeld RS, et al. Buprenorphine versus methadone maintenance handling for concurrent opioid dependence and cocaine abuse. Archives of General Psychiatry. 1997;54(8):713–720. [PubMed] [Google Scholar]
• Shaham Y, Erb S, Stewart J. Stress-induced relapse to heroin and cocaine seeking in rats: A review. Brain Research Reviews. 2000;33(1):13–33. [PubMed] [Google Scholar]
• U.S. Food and Drug Administration. FDA Talk Paper: FDA Announces Labeling Changes Following Cardiac Adverse Events With Habit Drug. 2001. April twenty, 2001. [ www.fda.gov/bbs/topics/ANSWERS/2001/ANS01076.html]
• Verebey KG, Mule SJ. Naltrexone (Trexan): A review of hepatotoxicity problems. In: Harris LS, editor. Problems of Drug Dependence, 1985: Proceedings of the 47th Annual Scientific Meeting, the Committee on Problems of Drug Dependence, Inc; Washington, DC: U.S. Government Printing Role; 1986. pp. 73–81. NIDA Enquiry Monograph 67. DHHS Publication No. (ADM) 86–1448. [Google Scholar]

mackinnotheir.blogspot.com

Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2851054/

Share this post